LB-01
Presbyopia
About Lento Bio
Lento Bio is pioneering a disease-modifying therapeutic approach for presbyopia, the universal age-related loss of near vision affecting over 1.8 billion people. Its lead candidate, LB-01, is a small molecule prodrug eye drop designed to cleave disulfide crosslinks in the lens, restoring flexibility and accommodation. The company is in the discovery/IND-enabling stage, with compelling preclinical data showing significant rejuvenation of lens flexibility in models. Lento Bio operates in a massive, underserved market with no approved disease-modifying treatments, positioning it as a potential disruptor in ophthalmology and aging biology.
View full company profileAbout Lento Bio
Lento Bio is pioneering a disease-modifying therapeutic approach for presbyopia, the universal age-related loss of near vision affecting over 1.8 billion people. Its lead candidate, LB-01, is a small molecule prodrug eye drop designed to cleave disulfide crosslinks in the lens, restoring flexibility and accommodation. The company is in the discovery/IND-enabling stage, with compelling preclinical data showing significant rejuvenation of lens flexibility in models. Lento Bio operates in a massive, underserved market with no approved disease-modifying treatments, positioning it as a potential disruptor in ophthalmology and aging biology.
View full company profileTherapeutic Areas
Other Presbyopia Drugs
| Drug | Company | Phase |
|---|---|---|
| Presbyopia Treatment | Viatris (2) | NDA Submitted |
| Presbyopia-Correcting ICL | STAAR Surgical | Research & Development |
| LB-02 | Lento Bio | Discovery |
| Presbyopia-Correcting Contact Lenses | Clerio Vision | Development |
| Intra-corneal Implant | MAG Optics | Pre-clinical |
| NVK029 | Vyluma | Phase 2 |
| ArtiPlus | Ophtec | Clinical Trials |
| BRIMOCHOL™ PF | Tenpoint Therapeutics | NDA Submitted |
| Qlosi™ | Orasis Pharmaceuticals | Approved |
| TSH‑001 | TSH Biopharm | Phase 1/2 |
| DE-128A | Santen Pharmaceutical | Phase 2 |
| YP-10 | Viatris | NDA Filed |